TABLE 1.
HLA-DR-binding assay of Mce2-derived peptidesa
| Peptide | IC50 (μM) for:
|
||||||
|---|---|---|---|---|---|---|---|
| DRB1*0101 (DR1) | DRB1*1501 (DR2) | DRB1*0301 (DR3) | DRB1*0401 (DR4) | DRB1*1101 (DR5) | DRB1*0701 (DR7) | DRB1*0801 (DR8) | |
| 1 (aa 163–175) | 30 | 15 | 0.45 | 0.8 | 2 | 0.025 | 100 |
| 2 (aa 95–108) | 0.02 | 0.008 | 8 | 2 | 0.4 | 0.025 | 0.15 |
| 3 (aa 49–64) | 0.8 | 1 | 100 | 8 | 1 | 0.4 | 10 |
| 4 (aa 278–290) | >100 | >100 | 25 | >100 | >100 | 0.6 | 0.2 |
| 5 (aa 17–29) | 20 | 1 | 30 | >100 | 18 | 0.07 | 100 |
| HA307–319 | 0.12 | 4 | 8 | 1.5 | 0.5 | 0.3 | 4 |
a
Synthesized Mce2-derived peptides are listed. Peptides were tested by ELISA for the competition of binding to HLA-DR of an indicator peptide and were compared to a promiscuous HLA-DR ligand from influenza hemagglutinin (HA307–319). The HLA-DR binding is expressed as the micromolar concentration of the competitor peptide able to inhibit the binding of the biotinylated indicator peptide by 50% (IC50 in micromolars). aa, amino acids.